Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP
Jump to navigation
Jump to search
Answer the questions:
- What are the 10 biggest for-profit companies in this field?
- How is the market distributed?
- Where are they located? Are there any incentives for specific locations?
- Correlate them with their main outputs (Data. Narratives. Tools)
- Understand and identify cases where these companies are “experimenting” or “adopting” commons-based approaches
- Identify these cases and treat them as entities that will also be placed in our mapping*device (the quadrants)
- Identify what companies are the “Microsofts” of the field and what companies are the “IBMs” of the field
Note on outputs: all these companies make their money primarily through developing and patenting drugs. The distinguishing factor seems to be that the largest of these companies produce the drugs themselves, while the smaller ones license these drugs to be produced by larger pharmaceutical companies
| 2006 Revenue ($m) | Headquarters | Primary Outputs | Instances of Commons-based approaches | |
| Amgen | 14268
|
Thousand Oaks, California | ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline | Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets |
| Genentech
|
9284
|
South San Francisco
|
synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process | ? |
| Genzyme
|
3187
|
Cambridge, Massachusetts
|
Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue | ? |
| Gilead Sciences
|
3026
|
Foster City, California | 11 commercial products
|
? |
| Biogen Idec
|
2683
|
Cambridge, Massachusetts
|
Treatments for Crohn's disease, non-Hodgkin's lymphoma, and multiple sclerosis | ? |
| Cephalon
|
1764
|
Frazer, Pennsylvania | Specializes in treating neurodegenerative diseases | ? |
| MedImmune
|
1277
|
Gaithersburg, Maryland | Only major drug prevents respiratory diseases in infants | ? |
| Celgene
|
899
|
Summit, New Jersey
|
treatments for erythema nodosum leprosum ("ENL") and multiple myeloma | ? |
| Abraxis BioScience
|
766
|
Los Angeles, California
|
uses patented nanoparticle technology to produce products for metastatic breast cancer | ? |
| ImClone Systems
|
678
|
New York, New York
|
acquired by Eli Lilly, tried to produce Erbitux for Colorectal Cancer, but failed to win FDA approval | ? |
Bibliography for Item 6 in BGP
Biotechnology_-_Genomic_and_Proteomics